Home » Stocks » Alterity Therapeutics

Alterity Therapeutics Limited (ATHE)

Stock Price: $2.54 USD 0.14 (5.83%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $2.65 +0.11 (4.33%) Aug 7, 7:04 PM

Stock Price Chart

Key Info

Market Cap 45.93M
Revenue (ttm) n/a
Net Income (ttm) -12.34M
Shares Out 18.08M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $2.54
Previous Close $2.40
Change ($) 0.14
Change (%) 5.83%
Day's Open 2.24
Day's Range 2.21 - 2.96
Day's Volume 2,959,505
52-Week Range 0.28 - 5.15

More Stats

Market Cap 45.93M
Enterprise Value 31.53M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 18.08M
Float 9.96M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share -1.36
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 6,771
Short Ratio 0.06
Short % of Float n/a
Beta 0.42
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 3.45
Revenue n/a
Operating Income -17.75M
Net Income -12.34M
Free Cash Flow -13.96M
Net Cash 14.40M
Net Cash / Share 0.80
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -56.63%
ROE -114.26%
ROIC -812.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$4.00*
Low
4.00
Current: $2.54
High
4.00
Target: 4.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue---0.140.180.360.150.190.160.22
Revenue Growth----19.33%-51.39%141.12%-19.18%19.55%-27.38%-
Gross Profit---0.140.180.360.150.190.160.22
Operating Income-17.75-11.32-10.04-13.34-16.92-20.40-11.10-6.55-5.43-3.96
Net Income-12.34-8.27-7.54-7.73-5.89-13.33-7.79-5.24-6.43-4.91
Shares Outstanding616534534534503428339288248228
Earnings Per Share-1.20-0.93-0.85-0.87-0.70-1.87-1.38-1.09-1.56-1.30
Operating Cash Flow-13.95-6.25-5.87-7.42-10.87-13.54-7.95-6.85-4.56-4.71
Capital Expenditures-0.01-0.06-0.03--0.03-0.02-0.02-0.03-0.01-0.02
Free Cash Flow-13.96-6.31-5.89-7.42-10.90-13.56-7.97-6.87-4.57-4.73
Cash & Equivalents14.4015.2421.8828.5934.9134.1713.355.648.845.23
Total Debt----0.010.100.870.340.36-
Net Cash / Debt14.4015.2421.8828.5934.9034.0712.485.308.485.23
Assets19.9118.7325.2833.7341.8341.6417.077.349.016.80
Liabilities3.362.641.592.362.723.953.101.722.081.57
Book Value16.5516.0823.6931.3739.1137.6913.975.626.935.23
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Alterity Therapeutics Limited
Employees 14
CEO Geoffrey Paul Kempler

Stock Information

Ticker Symbol ATHE
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ATHE

Description

Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidates include PBT434 that is in Phase I clinical trial for the treatment of Parkinson's disease and other movement disorders. It is also developing PBT2 for patients with Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.